News
Bristol Myers and Pfizer said on Thursday they will start selling their blockbuster blood thinner, Eliquis, directly to ...
The joint venture is launching a direct-to-consumer service of Eliquis after discussions with the Trump administration.
The companies’ new effort would bypass traditional middlemen to cut the drug’s monthly cost from a list price of around $606 ...
The program is the latest example of pharmaceutical companies bypassing traditional drug distribution channels for people who ...
Drugmakers will offer Eliquis at a 43% discount to uninsured U.S. patients, bypassing insurers and PBMs New $346 monthly ...
Bristol Myers and Pfizer will sell Eliquis directly to U.S. patients at a discounted rate with transparent pricing and ...
Explore more
1d
Zacks.com on MSNWill Increased Expenses Affect Bristol Myers' Performance?Bristol Myers Squibb BMY announced a strategic collaboration agreement with BioNTech BNTX for the global co-development and ...
Taking a page from Eli Lilly and Novo Nordisk, who have launched online programs to sell their diabetes and obesity drugs ...
Bristol Myers Squibb Co. closed 26.69% short of its 52-week high of $63.33, which the company achieved on March 11th.
4d
Barchart on MSNWhat to Expect From Bristol-Myers Squibb's Q2 2025 Earnings ReportBristol-Myers Squibb is set to announce its second-quarter results by the end of July, and analysts expect a notable drop in ...
Cigna sued Bristol Myers Squibb on Tuesday, accusing the drugmaker of violating U.S. antitrust law by keeping generic versions of its blockbuster blood cancer drug Pomalyst off the market so it could ...
(Reuters) -Bristol Myers and Pfizer said on Thursday they will start selling their blockbuster blood thinner, Eliquis, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results